The software, which delivers general anesthesia on its Aisys CS2 Anesthesia Delivery System, allows providers to set targets for end-tidal oxygen and anesthetic agents. Once set, the software achieves and maintains those targets regardless of hemodynamic and metabolic status changes.
“Anesthesia providers in the U.S. will have access to the most advanced anesthesia tools available to improve patient care,” Eric Ruedinger, general manager of GE Healthcare’s anesthesia and respiratory care business said in the press release. “As the long-standing global leader in anesthesia delivery, GE Healthcare invested in the development and clinical validation of this Et Control algorithm, and we are committed to creating clinically relevant solutions that will enhance anesthesia practices into the future.”
With this FDA approval, GE Healthcare will launch the Aisys CS2 Anesthesia Delivery System with Et Control in the U.S in the coming months.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
